Comparable stake leader
BlackRock, Inc.
SEC ownership of ARROWHEAD PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000879407.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
15 Jun 2026
- Public ticker
- ARWR on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
15 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000879407
- Issuer location
- Pasadena, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ARROWHEAD PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
15 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 12%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 12%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
12%
Avoro Capital Advisors LLC
8.3%
FMR LLC
5.2%
VANGUARD PORTFOLIO MANAGEMENT LLC
5.2%
VANGUARD CAPITAL MANAGEMENT LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
12%
from 13D/G
|
$1,138,727,235
18,161,519 shares
|
— | 31 Mar 2026 |
| Avoro Capital Advisors LLC |
13F
13D/G
Company
|
8.3%
from 13D/G
|
$670,889,937
10,699,999 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
5.2%
|
$478,720,814
7,349,107 shares
|
$0 | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
Vanguard Portfolio Management · Company
|
5.2%
|
$455,826,304
7,269,957 shares
|
$0 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5%
|
$443,997,071
7,081,293 shares
|
$0 | 31 Mar 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
4.6%
from 13D/G
|
$407,307,351
6,496,130 shares
|
— | 31 Mar 2026 |
| Christopher Richard Anzalone |
3/4/5
Chief Executive Officer, Director
|
2.7%
|
$251,799,942
3,792,739 shares
|
-$24,010,564 | 02 Jan 2026 |
| Patrick O'Brien |
3/4/5
COO
|
0.39%
|
$36,342,471
547,408 shares
|
-$3,123,349 | 06 Jan 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$37,882,496.
Buys
$0
Insiders: 0
Sells
$37,882,496
Insiders: 10
Net
-$37,882,496
Shares: -606,901
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 606,901
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 26,065 | $0 | $1,912,619 | -$1,912,619 |
| 3-6 | 0 | 164,570 | $0 | $10,747,188 | -$10,747,188 |
| 6-9 | 0 | 376,266 | $0 | $24,197,689 | -$24,197,689 |
| 9-12 | 0 | 40,000 | $0 | $1,025,000 | -$1,025,000 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to ARROWHEAD PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Christopher Richard Anzalone
Net 12M change
-$37,882,496
Latest report
15 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer, Director | $251,799,942 | -$24,010,564 | -8.7% | Filing P/S | 02 Jan 2026 |
| Patrick O'Brien | Coo | $36,342,471 | -$3,123,349 | -7.9% | Mixed | 06 Jan 2026 |
| James C. Hamilton | Chief Medical Officer | $17,021,850 | -$5,651,561 | -25% | Filing P/S | 23 Apr 2026 |
| Daniel Joseph Apel | Chief Financial Officer | $11,716,127 | -$934,285 | -7.4% | Filing P/S | 22 Apr 2026 |
| Kenneth Allen Myszkowski | Chief Financial Officer | $8,967,476 | Filing P/S | 04 Jan 2025 | ||
| Javier San Martin | Chief Medical Officer | $7,417,833 | Mixed | 04 Jan 2024 | ||
| Michael S. Perry | Director | $4,977,736 | -$991,738 | -17% | Mixed | 16 Dec 2025 |
| Mauro Ferrari | Director | $4,833,710 | -$1,020,513 | -17% | Filing P/S | 26 Dec 2025 |
| Hongbo Lu | Director | $3,998,682 | -$228,334 | -5.4% | Filing P/S | 12 May 2026 |
| James Hassard | Chief Commercial Officer | $3,951,878 | Mixed | 22 Jun 2021 | ||
| William D. Waddill | Director | $3,876,262 | -$566,038 | -13% | Filing P/S | 19 Dec 2025 |
| Tracie Oliver | Chief Commercial Officer | $3,213,265 | Filing P/S | 02 Jul 2024 | ||
| Douglas B. Given | Director | $2,736,641 | Filing P/S | 16 Dec 2024 | ||
| Victoria Vakiener | Director | $2,443,095 | -$679,491 | -22% | Filing P/S | 19 Dec 2025 |
| Adeoye Y. Olukotun | Director | $2,300,928 | -$676,623 | -23% | Filing P/S | 19 Dec 2025 |
| Douglas S. Ingram | Director | $1,869,396 | Mixed | 16 Dec 2025 | ||
| Marianne de Backer | Director | $1,168,448 | Mixed | 10 Jan 2023 | ||
| Matthew Gregory Cohen | Director | $745,001 | Median | 15 Jun 2026 |
Recent insider transactions for ARROWHEAD PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Matthew Gregory Cohen | ARWR | Common Stock | Award | 11,882 | 11,882 | 15 Jun 2026 | Direct | |||
| Hongbo Lu | ARWR | Common Stock | Sale | -5.4% | $228,334 | $76.88 | -2,970 | 52,012 | 12 May 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -4.22% | $750,000 | $75.00 | -10,000 | 226,958 | 23 Apr 2026 | Direct |
| Daniel Joseph Apel | ARWR | Common Stock | Sale | -7.44% | $934,285 | $71.35 | -13,095 | 162,905 | 22 Apr 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -4.05% | $641,900 | $64.19 | -10,000 | 236,958 | 05 Mar 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Award | 43.6% | 75,000 | 246,958 | 06 Jan 2026 | Direct | ||
| Daniel Joseph Apel | ARWR | Common Stock | Award | 74.1% | 75,000 | 176,200 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Award | 15.9% | 75,000 | 547,408 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Gift | -0.53% | -2,500 | 472,408 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Sale | -9.44% | $3,123,349 | $63.11 | -49,493 | 474,908 | 05 Jan 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -18.9% | $2,534,661 | $63.11 | -40,164 | 171,958 | 05 Jan 2026 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.35% | $871,703 | $66.10 | -13,187 | 3,792,739 | 02 Jan 2026 | Direct |
| Patrick O'Brien | ARWR | Common Stock | Gift | -0.53% | -2,800 | 524,401 | 31 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -1.34% | $3,575,575 | $69.13 | -51,726 | 3,805,926 | 29 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Options Exercise | 1.36% | 51,726 | 3,857,652 | 29 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Stock Option (right to buy Common Stock) | Options Exercise | -100% | -51,726 | 0 | 29 Dec 2025 | Direct | ||
| Mauro Ferrari | ARWR | Common Stock | Sale | -9.83% | $527,100 | $70.00 | -7,530 | 69,053 | 26 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.33% | $861,340 | $68.44 | -12,586 | 3,805,926 | 22 Dec 2025 | Direct |
| William D. Waddill | ARWR | Common Stock | Sale | -12.9% | $566,038 | $67.65 | -8,367 | 56,563 | 19 Dec 2025 | Direct |
| Victoria Vakiener | ARWR | Common Stock | Sale | -21.9% | $679,491 | $67.68 | -10,040 | 35,723 | 19 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.35% | $909,683 | $67.66 | -13,445 | 3,818,512 | 19 Dec 2025 | Direct |
| Adeoye Y. Olukotun | ARWR | Common Stock | Sale | -22.9% | $676,623 | $67.66 | -10,000 | 33,600 | 19 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -2.17% | $5,443,462 | $64.04 | -85,000 | 3,831,957 | 17 Dec 2025 | Direct |
| Mauro Ferrari | ARWR | Common Stock | Award | 11.4% | 7,819 | 76,583 | 16 Dec 2025 | Direct | ||
| Hongbo Lu | ARWR | Common Stock | Award | 16.6% | 7,819 | 54,982 | 16 Dec 2025 | Direct | ||
| Michael S. Perry | ARWR | Common Stock | Award | 6.78% | 7,819 | 123,059 | 16 Dec 2025 | Direct | ||
| Victoria Vakiener | ARWR | Common Stock | Award | 20.6% | 7,819 | 45,763 | 16 Dec 2025 | Direct | ||
| Douglas S. Ingram | ARWR | Common Stock | Award | 20.4% | 7,819 | 46,215 | 16 Dec 2025 | Direct | ||
| Adeoye Y. Olukotun | ARWR | Common Stock | Award | 21.8% | 7,819 | 43,600 | 16 Dec 2025 | Direct | ||
| William D. Waddill | ARWR | Common Stock | Award | 13.7% | 7,819 | 64,930 | 16 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -1.37% | $3,398,187 | $62.58 | -54,298 | 3,916,957 | 16 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -3.17% | $8,950,615 | $68.85 | -130,000 | 3,971,255 | 15 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Award | 4.59% | 180,000 | 4,101,255 | 12 Dec 2025 | Direct | ||
| Michael S. Perry | ARWR | Common Stock | Sale | -12.4% | $991,738 | $61.03 | -16,250 | 115,240 | 05 Dec 2025 | Direct |
| Mauro Ferrari | ARWR | Common Stock | Sale | -11.3% | $493,412 | $56.39 | -8,750 | 68,764 | 28 Nov 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -8.62% | $700,000 | $35.00 | -20,000 | 212,122 | 01 Oct 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -6.07% | $450,000 | $30.00 | -15,000 | 232,122 | 12 Sep 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -5.72% | $375,000 | $25.00 | -15,000 | 247,122 | 02 Sep 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -3.46% | $187,780 | $20.00 | -9,389 | 262,122 | 15 Aug 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -0.22% | $12,220 | $20.00 | -611 | 271,511 | 13 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.